Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Short

Showing results (591-600 of 659) with videos related to

Pageof 66
Sort By:
Blood Advances|May 27, 2026
Long-Term Outcomes of Azacitidine, Venetoclax and Gilteritinib in Newly Diagnosed FLT3-Mutated AMLNicholas J Short, Hagop M Kantarjian, Naval G Daver, et al.
Leukemia|February 27, 2020
A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemiaPrithviraj Bose, Srdan Verstovsek, Jorge E Cortes, et al.
Blood Advances|August 16, 2022
Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndromeCourtney D DiNardo, Sangeetha Venugopal, Curtis Lachowiez, et al.
Bone Marrow Transplantation|April 11, 2025
Barriers to allogeneic stem cell transplantation in responding patients with TP53-mutated acute myeloid leukemiaJayastu Senapati, Guillermo Garcia-Manero, Courtney D DiNardo, et al.
Cancer|August 9, 2025
Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3-tyrosine kinase domain mutations: Prognostic implications of NPM1 co-mutationSankalp Arora, Wei-Ying Jen, Musa Yilmaz, et al.
Blood Cancer Journal|September 22, 2023
Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agentsDanielle Hammond, Sanam Loghavi, Sa A Wang, et al.
BMJ Open|March 21, 2024
Comprehensive quality assessment for aphasia rehabilitation after stroke: protocol for a multicentre, mixed-methods studySam Harvey, Marissa Stone, Sally Zingelman, et al.
Blood|April 3, 2025
Blood-Based Proteomic Profiling Identifies OSMR as a Novel Biomarker of AML OutcomesPatrick K Reville, Bofei Wang, Jennifer Marvin-Peek, et al.
Blood Advances|May 9, 2022
High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapseNicholas J Short, Hagop Kantarjian, Farhad Ravandi, et al.
Leukemia & Lymphoma|April 20, 2022
A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemiaNicholas J Short, Gautam Borthakur, Naveen Pemmaraju, et al.
Pageof 66

Showing results (591-600 of 659) with videos related to

Sort By:
Pageof 66
Blood Advances|May 27, 2026
Long-Term Outcomes of Azacitidine, Venetoclax and Gilteritinib in Newly Diagnosed FLT3-Mutated AMLNicholas J Short, Hagop M Kantarjian, Naval G Daver, et al.
Leukemia|February 27, 2020
A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemiaPrithviraj Bose, Srdan Verstovsek, Jorge E Cortes, et al.
Blood Advances|August 16, 2022
Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndromeCourtney D DiNardo, Sangeetha Venugopal, Curtis Lachowiez, et al.
Bone Marrow Transplantation|April 11, 2025
Barriers to allogeneic stem cell transplantation in responding patients with TP53-mutated acute myeloid leukemiaJayastu Senapati, Guillermo Garcia-Manero, Courtney D DiNardo, et al.
Cancer|August 9, 2025
Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3-tyrosine kinase domain mutations: Prognostic implications of NPM1 co-mutationSankalp Arora, Wei-Ying Jen, Musa Yilmaz, et al.
Blood Cancer Journal|September 22, 2023
Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agentsDanielle Hammond, Sanam Loghavi, Sa A Wang, et al.
BMJ Open|March 21, 2024
Comprehensive quality assessment for aphasia rehabilitation after stroke: protocol for a multicentre, mixed-methods studySam Harvey, Marissa Stone, Sally Zingelman, et al.
Blood|April 3, 2025
Blood-Based Proteomic Profiling Identifies OSMR as a Novel Biomarker of AML OutcomesPatrick K Reville, Bofei Wang, Jennifer Marvin-Peek, et al.
Blood Advances|May 9, 2022
High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapseNicholas J Short, Hagop Kantarjian, Farhad Ravandi, et al.
Leukemia & Lymphoma|April 20, 2022
A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemiaNicholas J Short, Gautam Borthakur, Naveen Pemmaraju, et al.
Pageof 66